Botox for migraines: waste, high cost, and low adherence

Botox® is not much help either 

August 21, 2019

Finding the right treatment can be a real headache for migraine patients; for those who finally try it, it doesn’t look like Botox® is much help either

Patients who try Botox have not responded to other conventional migraine therapies. They have struggled to find relief from acute, debilitating headaches. This study looked at 2,500 patients who were new to Botox therapy. Treatment consists of injections given in the face, head and neck by a doctor in a health care setting.

Waste: Because of vial sizes and dosing, there is substantial drug waste. Drug waste and provider administration accounts for one-third of the drug’s $6,300 annual cost. Low adherence: Less than half of the patients completed the recommended four courses of quarterly treatments. This indicates treatment failure. High cost: The study found that Botox did not decrease total cost of care for patients with migraines. It was associated with a three-fold increase in total migraine-related costs.

Read more

OnabotulinumToxinA (Botox® ) and Migraine: Persistence, Utilization and Expenditure within the Botulinum Toxin Drug Class (Fall 2019)

Related research

Scientific presentations

August 21, 2021

Real-world CAR-T treatment costs can range from $700,000 to $1 million

CAR-T treatment costs more than the CAR-T product itself; Prime’s real-world study of…

Scientific presentations

August 1, 2021

Prime’s analytics uncovers the hidden ups and downs behind the flat drug trend for MS DMDs

Insights from integrated medical and pharmacy claims show a big upswing in one…

Scientific presentations

June 21, 2021

Break autoimmune (AI) into indication-specific info for actionable strategy

Prime uses integrated medical and pharmacy data and breaks down largest drug category…